Third Rock Ventures


Third Rock Ventures is an early-stage life sciences venture firm (founded 2007) that creates and builds biotechnology and biopharmaceutical companies. The firm provides company formation, discovery, operational leadership, board-level support and venture financing to advance companies from concept through clinical development and commercialization. Site metrics cited on the firm website: 18 years in operation, 72 portfolio companies and 23 marketed products.

Third Rock Ventures

Boston, Massachusetts, United States, North America


Services

Company discovery and strategy

Collaborative discovery to identify scientific fields, refine company concepts and develop company strategies with scientific founders and advisors.

Launch support and interim leadership

Financial, technical and human-resource support at company launch, including interim executive roles to execute early R&D strategy and recruit founding teams.

Build-stage operational and board support

Transition from interim roles to established management while providing board-level oversight, domain experts and firm resources to scale development and business operations.

Peer learning and operational tools (Beyond Great)

A firm-run learning community providing peer-to-peer networking, tools and operational resources for leaders across the portfolio.

Business development and partnership cultivation

Identification and cultivation of partnerships and transactions to create value for portfolio companies.

Financing and capital deployment

Provide venture financing at company creation and participate in follow-on financings across development stages.


Portfolio

Launch financing cited at $82M; focus on in vivo precision genome engineering for cancer immunotherapies.

#Genomic medicine / in vivo genome engineering

Jewel® Patch wearable cardioverter defibrillator received FDA approval.

#Medical device / wearable cardioverter defibrillator

Working on precision immunology approaches for antibody-driven diseases.

#Biotechnology / precision immunology

Developing genomic medicine approaches for neurodegenerative diseases.

#Biopharmaceuticals / genomic medicine for neurodegenerative diseases

Developing T-cell engager programs for autoimmune diseases.

#Biotechnology / autoimmune disease therapeutics

Developing medicines for cardiometabolic diseases; multiple clinical updates referenced.

#Biotechnology / cardiometabolic diseases

View All Portfolio Items

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.